Amarin fish­es for an­oth­er CFO as down­siz­ing takes hold; Cure­Vac makes a deal, then lines up No­var­tis ex­ec to lead de­vel­op­ment

→ Mired in flag­ging sales for Vas­cepa, the harsh re­al­i­ties of the cur­rent cli­mate in biotech have hit Amarin as they slice 40% of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.